'Best-Case Exit Strategy': Biogen (BIIB) Stock Falls as Takeover Rumor Denied, But Analysts Bullish on Takeover Prospect
Tweet Send to a Friend
Biogen (NASDAQ: BIIB) stock price is down over 6.5% in pre-open Thursday after Samsung Group denied it is engaged in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
